{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:19:58Z","timestamp":1762809598609,"version":"3.41.2"},"reference-count":263,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443141164"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.04.003","type":"book-chapter","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T20:43:40Z","timestamp":1715805820000},"page":"327-384","source":"Crossref","is-referenced-by-count":6,"title":["Current neuroprotective therapies and future prospects for motor neuron disease"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2024.04.003_bib1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s00415-006-0481-8","article-title":"CSF neurofilament protein (NFL) \u2013 A marker of active HIV-related neurodegeneration","volume":"254","author":"Abdulle","year":"2007","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients","volume":"15","author":"Abe","year":"2014","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S1474-4422(14)70219-4","article-title":"Analysis of amyotrophic lateral sclerosis as a multistep process: A population-based modelling study","volume":"13","author":"Al-Chalabi","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/jnnp-2020-323271","article-title":"Clinical staging in amyotrophic lateral sclerosis: Analysis of Edaravone Study 19","volume":"92","author":"Al-Chalabi","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2024.04.003_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/21678421.2013.778571","article-title":"Genetic and epigenetic studies of amyotrophic lateral sclerosis","volume":"14","author":"Al-Chalabi","year":"2013","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"issue":"Suppl. 5","key":"10.1016\/bs.irn.2024.04.003_bib6","first-page":"35","article-title":"DNA lesions, inducible DNA repair, and cell division: Three key factors in mutagenesis and carcinogenesis","volume":"101","author":"Ames","year":"1993","journal-title":"Environmental Health Perspectives"},{"key":"10.1016\/bs.irn.2024.04.003_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","article-title":"Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis","volume":"21","author":"Andrews","year":"2020","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib8","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/WCO.0000000000000983","article-title":"Amyotrophic lateral sclerosis is a systemic disease: Peripheral contributions to inflammation-mediated neurodegeneration","volume":"34","author":"Appel","year":"2021","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(94)05558-Z","article-title":"Evaluation of oxidative stress in patients with hyperlipidemia","volume":"117","author":"Araujo","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.irn.2024.04.003_bib10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.0b013e3182a823e0","article-title":"Analysis of start-up, retention, and adherence in ALS clinical trials","volume":"81","author":"Atassi","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib11","article-title":"Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial","volume":"30","author":"Babu","year":"2021","journal-title":"NeuroImage: Clinical"},{"key":"10.1016\/bs.irn.2024.04.003_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040706","article-title":"Interaction of mitochondrial calcium and ROS in neurodegeneration","volume":"11","author":"Baev","year":"2022","journal-title":"Cells"},{"key":"10.1016\/bs.irn.2024.04.003_bib13","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/21678421.2021.2016838","article-title":"Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: Potential limitations in current standard operating procedures","volume":"23","author":"Bakers","year":"2022","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/jnnp-2013-306865","article-title":"Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials","volume":"86","author":"Balendra","year":"2015","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/00207454.2020.1713776","article-title":"3-Nitrotyrosine: A versatile oxidative stress biomarker for major neurodegenerative diseases","volume":"130","author":"Bandookwala","year":"2020","journal-title":"The International Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ana.25431","article-title":"Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis","volume":"85","author":"Bandres-Ciga","year":"2019","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.freeradbiomed.2009.11.018","article-title":"Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target","volume":"48","author":"Barber","year":"2010","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Current Opinion in Biotechnology"},{"key":"10.1016\/bs.irn.2024.04.003_bib19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2024.04.003_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40478-018-0510-8","article-title":"Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945","volume":"6","author":"Beckmann","year":"2018","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1212\/WNL.0000000000002251","article-title":"How common are ALS plateaus and reversals?","volume":"86","author":"Bedlack","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89530","article-title":"ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity","volume":"2","author":"Beers","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/bs.irn.2024.04.003_bib23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ene.15573","article-title":"Effect of RNS60 in amyotrophic lateral sclerosis: A phase II multicentre, randomized, double-blind, placebo-controlled trial","volume":"30","author":"Beghi","year":"2023","journal-title":"European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2024.04.003_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: Treatment trials in the SOD1 mouse and in human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2024.04.003_bib25","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/brain\/awac394","article-title":"Neurofilament light chain in drug development for amyotrophic lateral sclerosis: A critical appraisal","volume":"146","author":"Benatar","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ana.25276","article-title":"Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion","volume":"84","author":"Benatar","year":"2018","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib27","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1212\/WNL.0000000000009559","article-title":"Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS","volume":"95","author":"Benatar","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12017-016-8396-8","article-title":"Identification of miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis patients","volume":"18","author":"Benigni","year":"2016","journal-title":"Neuromolecular Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib30","unstructured":"Bensimon, G., Leigh, N., & Mirocals_Study_Group. (2022). Modifying immune response and outcomes in ALS (MIROCALS): Design and results of a phase2b, double-blind randomized placebo controlled trial of low dose interleukin-2 (ldIL2) in ALS. In 33rd International MND Symposium. Virtual."},{"key":"10.1016\/bs.irn.2024.04.003_bib31","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1007\/s10072-022-05990-4","article-title":"Common genetic basis of ALS patients and soccer players may contribute to disease risk","volume":"43","author":"Ben-Zaken","year":"2022","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/21678421.2013.839708","article-title":"Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis","volume":"15","author":"Bergstrom","year":"2014","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib33","doi-asserted-by":"crossref","first-page":"e1466","DOI":"10.1212\/WNL.0000000000012632","article-title":"Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis","volume":"97","author":"Bjornevik","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib34","first-page":"90","article-title":"Panel of oxidative stress and inflammatory biomarkers in ALS: A pilot study","volume":"44","author":"Blasco","year":"2017","journal-title":"The Canadian Journal of Neurological"},{"key":"10.1016\/bs.irn.2024.04.003_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8","article-title":"Mitochondrial enzyme activity in amyotrophic lateral sclerosis: Implications for the role of mitochondria in neuronal cell death","volume":"46","author":"Borthwick","year":"1999","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(05)70326-4","article-title":"Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial","volume":"5","author":"Bourke","year":"2006","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039216","article-title":"Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis","volume":"7","author":"Brettschneider","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.04.003_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41598-020-80370-6","article-title":"Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS","volume":"11","author":"Brodovitch","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2024.04.003_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mus.27467","article-title":"Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19","volume":"65","author":"Brooks","year":"2022","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2024.04.003_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0896-6273(00)80272-X","article-title":"ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions","volume":"18","author":"Bruijn","year":"1997","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2024.04.003_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/21678421.2021.2016837","article-title":"Analysis of incidence of motor neuron disease in England 1998-2019: Use of three linked datasets","volume":"23","author":"Burchardt","year":"2022","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mcn.2013.07.007","article-title":"A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells","volume":"56","author":"Burkhardt","year":"2013","journal-title":"Molecular and Cellular Neurosciences"},{"key":"10.1016\/bs.irn.2024.04.003_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2021.108365","article-title":"Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer","volume":"787","author":"Caliri","year":"2021","journal-title":"Mutation Research. Reviews in Mutation Research"},{"key":"10.1016\/bs.irn.2024.04.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102844","article-title":"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial","volume":"59","author":"Camu","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13024-021-00475-y","article-title":"SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: Genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis","volume":"16","author":"Castelli","year":"2021","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib46","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/brain\/awac470","article-title":"Physical activity as an exogenous risk factor for amyotrophic lateral sclerosis: A review of the evidence","volume":"146","author":"Chapman","year":"2023","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41434-022-00375-w","article-title":"In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.irn.2024.04.003_bib48","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp-2013-306589","article-title":"Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis","volume":"86","author":"Chio","year":"2015","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib49","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.omtm.2021.03.017","article-title":"Adipose-derived stem cells protect motor neurons and reduce glial activation in both in vitro and in vivo models of ALS","volume":"21","author":"Ciervo","year":"2021","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/bs.irn.2024.04.003_bib50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/jnc.12642","article-title":"Hypoxia causes autophagic stress and derangement of metabolic adaptation in a cell model of amyotrophic lateral sclerosis","volume":"129","author":"Cimini","year":"2014","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2024.04.003_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/bs.irn.2024.04.003_bib52","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/brain\/awu120","article-title":"Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions","volume":"137","author":"Cooper-Knock","year":"2014","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib53","unstructured":"CORESTEM. (2019). Press report: First licensed stem cell therapy for ALS. www.nature.com\/articles\/d43747-020-00727-8."},{"key":"10.1016\/bs.irn.2024.04.003_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41573-021-00162-z","article-title":"Antisense technology: An overview and prospectus","volume":"20","author":"Crooke","year":"2021","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2024.04.003_bib55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2024.04.003_bib56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.27472","article-title":"A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis","volume":"65","author":"Cudkowicz","year":"2022","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2024.04.003_bib57","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib58","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1093\/hmg\/ddm226","article-title":"Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content","volume":"16","author":"De Vos","year":"2007","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.irn.2024.04.003_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev.neuro.31.061307.090711","article-title":"Role of axonal transport in neurodegenerative diseases","volume":"31","author":"De Vos","year":"2008","journal-title":"Annual Review of Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib60","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.nbd.2017.02.004","article-title":"Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?","volume":"105","author":"De Vos","year":"2017","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2024.04.003_bib61","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/brain\/awab006","article-title":"Long-read targeted sequencing uncovers clinicopathological associations for C9orf72-linked diseases","volume":"144","author":"Dejesus-Hernandez","year":"2021","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneurol.2014.78","article-title":"The role of FUS gene variants in neurodegenerative diseases","volume":"10","author":"Deng","year":"2014","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib63","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1080\/14789450.2019.1691919","article-title":"Shining a light on defective autophagy by proteomics approaches: implications for neurodegenerative illnesses","volume":"16","author":"Di Domenico","year":"2019","journal-title":"Expert Review of Proteomics"},{"key":"10.1016\/bs.irn.2024.04.003_bib64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/21678421.2021.2019279","article-title":"Drug treatments and interactions, disease progression and quality of life in ALS patients","volume":"23","author":"Diamanti","year":"2022","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib65","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ana.24198","article-title":"C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis","volume":"76","author":"Diekstra","year":"2014","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.redox.2016.10.003","article-title":"Nrf2 mediates redox adaptations to exercise","volume":"10","author":"Done","year":"2016","journal-title":"Redox Biology"},{"key":"10.1016\/bs.irn.2024.04.003_bib68","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuron.2013.10.015","article-title":"RNA toxicity from the ALS\/FTD C9ORF72 expansion is mitigated by antisense intervention","volume":"80","author":"Donnelly","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/bs.irn.2024.04.003_bib69","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1212\/WNL.0b013e31828f18ac","article-title":"Cognitive changes predict functional decline in ALS: A population-based longitudinal study","volume":"80","author":"Elamin","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib70","unstructured":"EMA_GUIDANCE_DOCUMENT. (2016). Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)."},{"key":"10.1016\/bs.irn.2024.04.003_bib71","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/cns.13894","article-title":"Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients","volume":"28","author":"Esselin","year":"2022","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/bs.irn.2024.04.003_bib72","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/ejn.15608","article-title":"Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis","volume":"55","author":"Estevez-Silva","year":"2022","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib73","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1474-4422(18)30054-1","article-title":"Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study","volume":"17","author":"Fang","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10654-015-0077-7","article-title":"Amyotrophic lateral sclerosis among cross-country skiers in Sweden","volume":"31","author":"Fang","year":"2016","journal-title":"European Journal of Epidemiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib75","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41593-019-0530-0","article-title":"Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein","volume":"22","author":"Farhan","year":"2019","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib76","unstructured":"FDA_BRIEFING_DOCUMENT. (2023). NDA #215887 Tofersen."},{"key":"10.1016\/bs.irn.2024.04.003_bib77","unstructured":"FDA_GUIDANCE_DOCUMENT. (2019). Amyotrophic lateral sclerosis: Developing drugs for treatment guidance for industry."},{"key":"10.1016\/bs.irn.2024.04.003_bib78","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2024.04.003_bib79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acn3.51648","article-title":"Effects of PB-TURSO on the transcriptional and metabolic landscape of sporadic ALS fibroblasts","volume":"9","author":"Fels","year":"2022","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-023-00619-2","article-title":"Opinion: More mouse models and more translation needed for ALS","volume":"18","author":"Fisher","year":"2023","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-5918-8-1","article-title":"Acute exercise and oxidative stress: A 30 year history","volume":"8","author":"Fisher-Wellman","year":"2009","journal-title":"Dynamic Medicine: DM"},{"key":"10.1016\/bs.irn.2024.04.003_bib82","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamaneurol.2019.4490","article-title":"Development and validation of the rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS)","volume":"77","author":"Fournier","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib83","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/21678421.2022.2153607","article-title":"Clinically meaningful change: Evaluation of the rasch-built overall amyotrophic lateral sclerosis disability scale (ROADS) and the ALSFRS-R","volume":"24","author":"Fournier","year":"2023","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib84","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.irn.2024.04.003_bib85","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature14974","article-title":"GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport","volume":"525","author":"Freibaum","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2024.04.003_bib86","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/2051-5960-1-42","article-title":"Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis","volume":"1","author":"Freischmidt","year":"2013","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib87","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","article-title":"Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent","volume":"24","author":"Fujimori","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib88","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3389\/fneur.2020.00377","article-title":"The chitinases as biomarkers for amyotrophic lateral sclerosis: Signals from the CNS and beyond","volume":"11","author":"Gaur","year":"2020","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib89","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/21678421.2022.2154678","article-title":"MiToS and King\u2019s staging as clinical outcome measures in ALS: A retrospective analysis of the FORTITUDE-ALS trial","volume":"24","author":"Gebrehiwet","year":"2023","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai7866","article-title":"Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis","volume":"9","author":"Gendron","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib91","doi-asserted-by":"crossref","first-page":"fcab141","DOI":"10.1093\/braincomms\/fcab141","article-title":"Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2","volume":"3","author":"Giovannelli","year":"2021","journal-title":"Brain Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib92","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41582-022-00751-5","article-title":"Prospects for gene replacement therapies in amyotrophic lateral sclerosis","volume":"19","author":"Giovannelli","year":"2023","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1080\/21678421.2019.1632899","article-title":"Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: The Lighthouse trial","volume":"20","author":"Gold","year":"2019","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib94","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00415-010-5609-1","article-title":"Progression in ALS is not linear but is curvilinear","volume":"257","author":"Gordon","year":"2010","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib95","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-023-03903-3","article-title":"Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx(R)) in ALS patients: Phase I\/IIa clinical trial results","volume":"21","author":"Gotkine","year":"2023","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib96","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.bbadis.2006.01.004","article-title":"Genetics of familial and sporadic amyotrophic lateral sclerosis","volume":"1762","author":"Gros-Louis","year":"2006","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/bs.irn.2024.04.003_bib98","doi-asserted-by":"crossref","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"10.1016\/bs.irn.2024.04.003_bib99","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41467-017-00911-y","article-title":"HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients","volume":"8","author":"Guo","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib100","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2024.04.003_bib101","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/0002-9343(91)90279-7","article-title":"Reactive oxygen species in living systems: Source, biochemistry, and role in human disease","volume":"91","author":"Halliwell","year":"1991","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib102","doi-asserted-by":"crossref","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","article-title":"Amyotrophic lateral sclerosis","volume":"3","author":"Hardiman","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"key":"10.1016\/bs.irn.2024.04.003_bib103","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1474-4422(17)30163-1","article-title":"Edaravone: A new treatment for ALS on the horizon?","volume":"16","author":"Hardiman","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib104","article-title":"Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis","author":"Harvey","year":"2022","journal-title":"BioRxiv"},{"key":"10.1016\/bs.irn.2024.04.003_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/biom11030437","article-title":"Role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis: Antioxidant metalloenzymes and therapeutic strategies","volume":"11","author":"Hemerkova","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/bs.irn.2024.04.003_bib106","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/emmm.201201544","article-title":"Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival","volume":"5","author":"Henkel","year":"2013","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib107","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/nan.12148","article-title":"Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones","volume":"40","author":"Highley","year":"2014","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib109","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1523\/JNEUROSCI.3582-16.2017","article-title":"MicroRNA profiling reveals marker of motor neuron disease in ALS models","volume":"37","author":"Hoye","year":"2017","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omtn.2018.04.015","article-title":"Translating SOD1 gene silencing toward the clinic: A highly efficacious, off-target-free, and biomarker-supported strategy for fALS","volume":"12","author":"Iannitti","year":"2018","journal-title":"Molecular Therapy \u2013 Nucleic Acids"},{"key":"10.1016\/bs.irn.2024.04.003_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101707","article-title":"Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial","volume":"53","author":"Imamura","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3962","article-title":"The Src\/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis","volume":"9","author":"Imamura","year":"2017","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib113","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2990.1993.tb00443.x","article-title":"Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease","volume":"19","author":"Ince","year":"1993","journal-title":"Neuropathology and Applied Neurobiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/ncn3.12490","article-title":"Real-world safety of the novel, free radical scavenger edaravone for amyotrophic lateral sclerosis patients: Data from the post-marketing surveillance SUNRISE Japan","volume":"9","author":"Ishizaki","year":"2021","journal-title":"Neurology and Clinical Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib115","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1038\/s41598-017-06953-y","article-title":"TDP-43 stabilises the processing intermediates of mitochondrial transcripts","volume":"7","author":"Izumikawa","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2024.04.003_bib116","doi-asserted-by":"crossref","first-page":"1054006","DOI":"10.3389\/fphar.2022.1054006","article-title":"New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022","volume":"13","author":"Jiang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.04.003_bib117","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.freeradbiomed.2021.07.022","article-title":"NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS","volume":"173","author":"Jimenez-Villegas","year":"2021","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib118","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of TDP-43 propagation in neurodegenerative diseases: Integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Experimental & Molecular Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103397","article-title":"Physical exercise is a risk factor for amyotrophic lateral sclerosis: Convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes","volume":"68","author":"Julian","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fnmol.2017.00251","article-title":"Cellular chaperones as therapeutic targets in ALS to restore protein homeostasis and improve cellular function","volume":"10","author":"Kalmar","year":"2017","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib121","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1039\/C7MO00114B","article-title":"Proteomic profile of 4-PBA treated human neuronal cells during ER stress","volume":"14","author":"Kaur","year":"2018","journal-title":"Molecular Omics"},{"key":"10.1016\/bs.irn.2024.04.003_bib122","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/neup.12716","article-title":"Astrocytes release glutamate via cystine\/glutamate antiporter upregulated in response to increased oxidative stress related to sporadic amyotrophic lateral sclerosis","volume":"40","author":"Kazama","year":"2020","journal-title":"Neuropathology: Official Journal of the Japanese Society of Neuropathology"},{"key":"10.1016\/bs.irn.2024.04.003_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101601","article-title":"Status of ALS treatment, insights into therapeutic challenges and dilemmas","volume":"12","author":"Khamaysa","year":"2022","journal-title":"Journal of Personalized Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib124","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","article-title":"Improving clinical trial outcomes in amyotrophic lateral sclerosis","volume":"17","author":"Kiernan","year":"2021","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib125","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/brain\/awh503","article-title":"Mutant SOD1 alters the motor neuronal transcriptome: Implications for familial ALS","volume":"128","author":"Kirby","year":"2005","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib126","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.biocel.2019.03.009","article-title":"Antisense oligonucleotide therapies for amyotrophic lateral sclerosis: Existing and emerging targets","volume":"110","author":"Klim","year":"2019","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/bs.irn.2024.04.003_bib127","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","article-title":"ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair","volume":"22","author":"Klim","year":"2019","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13024-020-00386-4","article-title":"Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations","volume":"15","author":"Konopka","year":"2020","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-021-01615-z","article-title":"Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis","volume":"28","author":"Korobeynikov","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib130","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.cdd.4400387","article-title":"The mitochondrion as an integrator\/coordinator of cell death pathways","volume":"5","author":"Kroemer","year":"1998","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/bs.irn.2024.04.003_bib131","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib132","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/bs.irn.2024.04.003_bib133","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neubiorev.2016.04.007","article-title":"Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: A systematic review","volume":"66","author":"Lacorte","year":"2016","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/bs.irn.2024.04.003_bib134","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.celrep.2013.10.049","article-title":"Hexanucleotide repeats in ALS\/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic","volume":"5","author":"Lee","year":"2013","journal-title":"Cell Reports"},{"key":"10.1016\/bs.irn.2024.04.003_bib135","doi-asserted-by":"crossref","first-page":"859","DOI":"10.15252\/emmm.201607486","article-title":"Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to the asymptomatic phase of ALS\/FTD","volume":"9","author":"Lehmer","year":"2017","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib136","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuroscience.2015.03.061","article-title":"Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model","volume":"298","author":"Li","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib137","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fnagi.2016.00290","article-title":"Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: A meta-analysis","volume":"8","author":"Li","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib138","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","article-title":"Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS","volume":"237","author":"Liao","year":"2012","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib139","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2024.04.003_bib140","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","article-title":"Epidemiology of amyotrophic lateral sclerosis: An update of recent literature","volume":"32","author":"Longinetti","year":"2019","journal-title":"Current Opinion in Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib141","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis","volume":"267","author":"Lunetta","year":"2020","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib142","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00401-013-1181-y","article-title":"Dipeptide repeat protein pathology in C9ORF72 mutation cases: Clinico-pathological correlations","volume":"126","author":"Mackenzie","year":"2013","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.irn.2024.04.003_bib143","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib144","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/17482968.2011.633268","article-title":"Online assessment of ALS functional rating scale compares well to in-clinic evaluation: A prospective trial","volume":"13","author":"Maier","year":"2012","journal-title":"Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases"},{"key":"10.1016\/bs.irn.2024.04.003_bib145","doi-asserted-by":"crossref","first-page":"1067954","DOI":"10.3389\/fnagi.2023.1067954","article-title":"Association of the risk factor UNC13A with survival and upper motor neuron involvement in amyotrophic lateral sclerosis","volume":"15","author":"Manini","year":"2023","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib146","first-page":"1813","article-title":"Pictorial review of glutamate excitotoxicity: Fundamental concepts for neuroimaging","volume":"22","author":"Mark","year":"2001","journal-title":"AJNR. American Journal of Neuroradiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib147","doi-asserted-by":"crossref","first-page":"25663","DOI":"10.1038\/srep25663","article-title":"CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves","volume":"6","author":"Martinez-Muriana","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2024.04.003_bib148","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/ene.14393","article-title":"Amyotrophic lateral sclerosis: A clinical review","volume":"27","author":"Masrori","year":"2020","journal-title":"European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies"},{"key":"10.1016\/bs.irn.2024.04.003_bib149","article-title":"Serum neurofilaments in motor neuron disease and their utility in differentiating ALS, PMA and PLS","volume":"13","author":"Mccluskey","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/bs.irn.2024.04.003_bib150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/ane.13345","article-title":"Military service and related risk factors for amyotrophic lateral sclerosis","volume":"143","author":"Mckay","year":"2021","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/bs.irn.2024.04.003_bib151","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.freeradbiomed.2013.04.018","article-title":"S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis","volume":"61","author":"Mead","year":"2013","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib152","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","article-title":"Amyotrophic lateral sclerosis: A neurodegenerative disorder poised for successful therapeutic translation","volume":"22","author":"Mead","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/bs.irn.2024.04.003_bib153","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib154","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib155","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1073\/pnas.1314085111","article-title":"Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS","volume":"111","author":"Meyer","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2024.04.003_bib156","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib157","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2003715","article-title":"Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS","volume":"383","author":"Miller","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib158","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/01.wnl.0000333251.36681.a5","article-title":"A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis","volume":"72","author":"Mitchell","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib159","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1073\/pnas.1818415116","article-title":"Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects","volume":"116","author":"Mitra","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2024.04.003_bib160","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1474-4422(14)70129-2","article-title":"Clinical trials in amyotrophic lateral sclerosis: Why so many negative trials and how can trials be improved?","volume":"13","author":"Mitsumoto","year":"2014","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib161","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/21678421.2019.1632346","article-title":"Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial","volume":"21","author":"Mora","year":"2020","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib162","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.stem.2023.04.017","article-title":"Phase 1\/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery","volume":"30","author":"Morimoto","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/bs.irn.2024.04.003_bib163","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.freeradbiomed.2015.10.412","article-title":"Vitamin C and E supplementation prevents some of the cellular adaptations to endurance-training in humans","volume":"89","author":"Morrison","year":"2015","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib164","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 suppression with adeno-associated virus and microRNA in familial ALS","volume":"383","author":"Mueller","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib165","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/s41598-017-02364-1","article-title":"Age-related penetrance of the C9orf72 repeat expansion","volume":"7","author":"Murphy","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.irn.2024.04.003_bib166","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/jnnp-2015-310509","article-title":"Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): A 15-month longitudinal multicentre trial","volume":"86","author":"Neuwirth","year":"2015","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib167","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.clinph.2018.04.614","article-title":"Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centres","volume":"129","author":"Neuwirth","year":"2018","journal-title":"Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib168","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"44","author":"Nourelden","year":"2023","journal-title":"Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib169","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ana.25302","article-title":"Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis","volume":"84","author":"Oh","year":"2018","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib170","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-510X(97)00181-0","article-title":"Familial ALS is associated with mutations in all exons of SOD1: A novel mutation in exon 3 (Gly72Ser)","volume":"153","author":"Orrell","year":"1997","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2024.04.003_bib171","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2217\/nmt-2021-0042","article-title":"MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb\/III study: COMBAT-ALS study design","volume":"11","author":"Oskarsson","year":"2021","journal-title":"Neurodegenerative Disease Management"},{"key":"10.1016\/bs.irn.2024.04.003_bib172","first-page":"1","article-title":"Adaptive platform trials to transform ALS therapy development","author":"Paganoni","year":"2022","journal-title":"Ann Neurol"},{"key":"10.1016\/bs.irn.2024.04.003_bib173","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1212\/WNL.0000000000204032","article-title":"Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)","volume":"100","author":"Paganoni","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib174","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","article-title":"Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: Long-term results from the CENTAUR trial","volume":"93","author":"Paganoni","year":"2022","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMoa1916945","article-title":"Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis","volume":"383","author":"Paganoni","year":"2020","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib176","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mus.27569","article-title":"Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes","volume":"66","author":"Paganoni","year":"2022","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2024.04.003_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.03.002","article-title":"The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: Potential targets for neurotherapeutics","volume":"161","author":"Pajarillo","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.04.003_bib178","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bph.15221","article-title":"Protein kinase inhibitors for amyotrophic lateral sclerosis therapy","volume":"178","author":"Palomo","year":"2021","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.04.003_bib179","first-page":"11","article-title":"Oxidative stress as a therapeutic target in amyotrophic lateral sclerosis: Opportunities and limitations","author":"Park","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/bs.irn.2024.04.003_bib180","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/cpf.12108","article-title":"Influence of exercise intensity on systemic oxidative stress and antioxidant capacity","volume":"34","author":"Parker","year":"2014","journal-title":"Clinical Physiology and Functional Imaging"},{"key":"10.1016\/bs.irn.2024.04.003_bib181","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ana.25932","article-title":"Blood metal levels and amyotrophic lateral sclerosis risk: A prospective cohort","volume":"89","author":"Peters","year":"2021","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib182","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1212\/WNL.0000000000004029","article-title":"Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease","volume":"88","author":"Poesen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib183","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/21678421.2020.1752250","article-title":"Increased risk and early onset of ALS in professional players from Italian Soccer Teams","volume":"21","author":"Pupillo","year":"2020","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib184","unstructured":"QUINTANILLA-DIECK. (2022). HEALEY ALS platform trial update: Zilucoplan arm stopped early for futility."},{"key":"10.1016\/bs.irn.2024.04.003_bib185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm1205","article-title":"Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model","volume":"11","author":"Ralph","year":"2005","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib186","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s43588-022-00299-w","article-title":"Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data","volume":"2","author":"Ramamoorthy","year":"2022","journal-title":"Nature Computational Science"},{"key":"10.1016\/bs.irn.2024.04.003_bib187","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jnen\/nly047","article-title":"Systematic screening of ubiquitin\/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation","volume":"77","author":"Ramos-Campoy","year":"2018","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib188","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/hmg\/8.8.1451","article-title":"Variation in the biochemical\/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds","volume":"8","author":"Ratovitski","year":"1999","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.irn.2024.04.003_bib189","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41434-022-00349-y","article-title":"Curing SMA: Are we there yet?","volume":"30","author":"Reilly","year":"2023","journal-title":"Gene Therapy"},{"key":"10.1016\/bs.irn.2024.04.003_bib190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: The next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib191","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/brain\/awr351","article-title":"A proposed staging system for amyotrophic lateral sclerosis","volume":"135","author":"Roche","year":"2012","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib192","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1021\/bi026979d","article-title":"Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria","volume":"42","author":"Rodrigues","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/bs.irn.2024.04.003_bib193","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bbadis.2017.06.004","article-title":"Novel insights into the antioxidant role of tauroursodeoxycholic acid in experimental models of Parkinson\u2019s disease","volume":"1863","author":"Rosa","year":"2017","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Molecular Basis of Disease"},{"key":"10.1016\/bs.irn.2024.04.003_bib194","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/364362c0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"364","author":"Rosen","year":"1993","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2024.04.003_bib195","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030537","article-title":"SOD-1 variants in amyotrophic lateral sclerosis: Systematic re-evaluation according to ACMG-AMP guidelines","volume":"13","author":"Ruffo","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/bs.irn.2024.04.003_bib196","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/acn3.51096","article-title":"Improved ALS clinical trials through frequent at-home self-assessment: A proof of concept study","volume":"7","author":"Rutkove","year":"2020","journal-title":"Annals of Clinical and Translational Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib197","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jamaneurol.2019.2044","article-title":"Lifetime risk and heritability of amyotrophic lateral sclerosis","volume":"76","author":"Ryan","year":"2019","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib198","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/glia.20210","article-title":"Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis","volume":"51","author":"Sargsyan","year":"2005","journal-title":"Glia"},{"key":"10.1016\/bs.irn.2024.04.003_bib199","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/WNL.47.2.535","article-title":"Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis","volume":"47","author":"Sasaki","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib200","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1093\/brain\/awaa340","article-title":"Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis","volume":"143","author":"Sassani","year":"2020","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib201","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/21678421.2023.2216223","article-title":"COURAGE-ALS: A randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success","volume":"24","author":"Shefner","year":"2023","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib202","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21678421.2020.1822410","article-title":"A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS","volume":"22","author":"Shefner","year":"2021","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1016\/bs.irn.2024.04.003_bib203","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087398","article-title":"The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis","volume":"9","author":"Shepheard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.04.003_bib204","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/jnnp-2020-325014","article-title":"Value of systematic genetic screening of patients with amyotrophic lateral sclerosis","volume":"92","author":"Shepheard","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib205","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1212\/WNL.0000000000003741","article-title":"Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS","volume":"88","author":"Shepheard","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib206","first-page":"326","article-title":"Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole","volume":"67","author":"Sivori","year":"2007","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/bs.irn.2024.04.003_bib207","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/brain\/awz419","article-title":"Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis","volume":"143","author":"Smethurst","year":"2020","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib208","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.661447","article-title":"C9ORF72: What it is, what it does, and why it matters","volume":"15","author":"Smeyers","year":"2021","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib209","first-page":"11","article-title":"Physical-exercise-induced antioxidant effects on the brain and skeletal muscle","author":"Souza","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/bs.irn.2024.04.003_bib210","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1126\/science.1154584","article-title":"TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis","volume":"319","author":"Sreedharan","year":"2008","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.irn.2024.04.003_bib211","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","article-title":"Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression","volume":"89","author":"Steinacker","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib212","first-page":"3","article-title":"Why should we care about astrocytes in a motor neuron disease?","author":"Stoklund Dittlau","year":"2023","journal-title":"Frontiers in Molecular Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib213","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1001\/jamaneurol.2016.0594","article-title":"Association of environmental toxins with amyotrophic lateral sclerosis","volume":"73","author":"Su","year":"2016","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib214","doi-asserted-by":"crossref","first-page":"45083","DOI":"10.1074\/jbc.M111.293282","article-title":"4-Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells","volume":"286","author":"Suaud","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.irn.2024.04.003_bib215","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-based therapies for neurodegenerative diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib216","first-page":"1308","article-title":"Clinical trials in the ALS syndrome: It is time for change","volume":"90","author":"Swash","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib217","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/hmg\/ddt028","article-title":"Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS","volume":"22","author":"Taes","year":"2013","journal-title":"Human Molecular Genetics"},{"key":"10.1016\/bs.irn.2024.04.003_bib218","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib219","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/ana.25841","article-title":"The distinct traits of the UNC13A polymorphism in amyotrophic lateral sclerosis","volume":"88","author":"Tan","year":"2020","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib220","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib221","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2019-320442","article-title":"CSF chitinase proteins in amyotrophic lateral sclerosis","volume":"90","author":"Thompson","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib222","doi-asserted-by":"crossref","first-page":"fcac029","DOI":"10.1093\/braincomms\/fcac029","article-title":"Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain","volume":"4","author":"Thompson","year":"2022","journal-title":"Brain Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib223","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000465","article-title":"Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study","volume":"5","author":"Thonhoff","year":"2018","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/bs.irn.2024.04.003_bib224","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/jnnp-2021-328470","article-title":"Review of disease-modifying drug trials in amyotrophic lateral sclerosis","volume":"93","author":"Tornese","year":"2022","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib225","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12974-016-0620-9","article-title":"Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis","volume":"13","author":"Trias","year":"2016","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/bs.irn.2024.04.003_bib226","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s40478-022-01421-9","article-title":"Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: Evidence for multifaceted pathways underlying neurodegeneration","volume":"10","author":"Trist","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.irn.2024.04.003_bib227","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1093\/brain\/awac165","article-title":"Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord","volume":"145","author":"Trist","year":"2022","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2024.04.003_bib228","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.expneurol.2014.09.021","article-title":"Treadmill exercise activates Nrf2 antioxidant system to protect the nigrostriatal dopaminergic neurons from MPP+ toxicity","volume":"263","author":"Tsou","year":"2015","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib229","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.nbd.2003.12.012","article-title":"Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study","volume":"15","author":"Turner","year":"2004","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2024.04.003_bib230","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1212\/WNL.0000000000003067","article-title":"Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population","volume":"87","author":"Umoh","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib231","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000089620","article-title":"Excitotoxicity and amyotrophic lateral sclerosis","volume":"2","author":"Van Damme","year":"2005","journal-title":"Neuro-Degenerative Diseases"},{"key":"10.1016\/bs.irn.2024.04.003_bib232","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1152\/jn.2002.88.3.1279","article-title":"GluR2-dependent properties of AMPA receptors determine the selective vulnerability of motor neurons to excitotoxicity","volume":"88","author":"Van Damme","year":"2002","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/bs.irn.2024.04.003_bib233","article-title":"Results from the phase 1 trial and open-label extension evaluating BIIB078 in adults with C9orf72-ALS","author":"Van Den Berg","year":"2022","journal-title":"ENCALS"},{"key":"10.1016\/bs.irn.2024.04.003_bib234","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/jnnp-2020-325377","article-title":"Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions","volume":"92","author":"Van Der Ende","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib235","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"Van Deutekom","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib236","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1212\/WNL.0000000000004606","article-title":"Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials","volume":"89","author":"Van Eijk","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib237","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/WNL.0000000000012545","article-title":"Innovating clinical trials for amyotrophic lateral sclerosis: Challenging the established order","volume":"97","author":"Van Eijk","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib238","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1212\/WNL.0000000000006855","article-title":"Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials","volume":"92","author":"Van Eijk","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib239","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gde.2017.02.008","article-title":"Relationship between C9orf72 repeat size and clinical phenotype","volume":"44","author":"Van Mossevelde","year":"2017","journal-title":"Current Opinion in Genetics & Development"},{"key":"10.1016\/bs.irn.2024.04.003_bib240","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ng.3622","article-title":"Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis","volume":"48","author":"Van Rheenen","year":"2016","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.irn.2024.04.003_bib241","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41588-021-00973-1","article-title":"Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology","volume":"53","author":"Van Rheenen","year":"2021","journal-title":"Nature Genetics"},{"key":"10.1016\/bs.irn.2024.04.003_bib242","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3389\/fneur.2019.00291","article-title":"Biomarkers in motor neuron disease: A state of the art review","volume":"10","author":"Verber","year":"2019","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib243","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib244","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/jnnp-2019-321916","article-title":"Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes","volume":"91","author":"Vu","year":"2020","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib245","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.14645","article-title":"Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the veterans affairs health care system","volume":"3","author":"Vu","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/bs.irn.2024.04.003_bib246","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102036","article-title":"Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): A phase 2, randomised, double-blind, placebo-controlled trial and open label extension","volume":"60","author":"Vucic","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib247","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136039","article-title":"Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS","volume":"759","author":"Vucic","year":"2021","journal-title":"Neuroscience Letters"},{"key":"10.1016\/bs.irn.2024.04.003_bib248","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/jamaneurol.2020.4300","article-title":"Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: A randomized clinical trial","volume":"78","author":"Wainger","year":"2021","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib249","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/nn.4604","article-title":"C9orf72 expansion disrupts ATM-mediated chromosomal break repair","volume":"20","author":"Walker","year":"2017","journal-title":"Nature Neuroscience"},{"key":"10.1016\/bs.irn.2024.04.003_bib250","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.4130","article-title":"The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity","volume":"22","author":"Wang","year":"2016","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2024.04.003_bib251","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.15252\/embj.201694401","article-title":"The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy","volume":"35","author":"Webster","year":"2016","journal-title":"The EMBO Journal"},{"key":"10.1016\/bs.irn.2024.04.003_bib252","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(18)30089-9","article-title":"Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model","volume":"17","author":"Westeneng","year":"2018","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib253","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s11064-020-02959-7","article-title":"Astrocyte diversity: Current insights and future directions","volume":"45","author":"Westergard","year":"2020","journal-title":"Neurochemical Research"},{"key":"10.1016\/bs.irn.2024.04.003_bib254","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.0022-3042.2001.00731.x","article-title":"Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients","volume":"80","author":"Wiedemann","year":"2002","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2024.04.003_bib255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis","volume":"79","author":"Witzel","year":"2022","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib256","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064173","article-title":"Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): A multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease","volume":"12","author":"Wong","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/bs.irn.2024.04.003_bib97","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial","volume":"16","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib257","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1007\/s00415-021-10508-7","article-title":"Prognostic models for amyotrophic lateral sclerosis: A systematic review","volume":"268","author":"Xu","year":"2021","journal-title":"Journal of Neurology"},{"key":"10.1016\/bs.irn.2024.04.003_bib258","article-title":"Neurofilaments as biomarkers for amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"11","author":"Xu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.04.003_bib259","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/17482960600881870","article-title":"Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)","volume":"7","author":"Yoshino","year":"2006","journal-title":"Amyotrophic Lateral Sclerosis: Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases"},{"key":"10.1016\/bs.irn.2024.04.003_bib260","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2020.09.020","article-title":"TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS\/STING in ALS","volume":"183","author":"Yu","year":"2020","journal-title":"Cell"},{"key":"10.1016\/bs.irn.2024.04.003_bib261","doi-asserted-by":"crossref","first-page":"14941","DOI":"10.1074\/jbc.M110.211029","article-title":"Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease","volume":"286","author":"Zhou","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.irn.2024.04.003_bib262","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","article-title":"Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis","volume":"88","author":"Zou","year":"2017","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2024.04.003_bib263","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nicl.2015.01.009","article-title":"Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [(11)C]-PBR28","volume":"7","author":"Zurcher","year":"2015","journal-title":"NeuroImage: Clinical"}],"container-title":["International Review of Neurobiology","Motor Neurone Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:40:15Z","timestamp":1753461615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443141164"],"references-count":263,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.04.003","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2024]]}}}